Two years after scrapping three hemophilia trials, Novo Nordisk plots route to FDA with new PhIII data - Endpoints News

Novo Nordisk continues to move forward with its once-daily monoclonal antibody for hemophilia A or B treatment aiming to stop excessive bleeding events before they happen, touting new Phase III data Sunday. The Danish pharma put out word that a pivotal trial …

No­vo Nordisk con­tin­ues to move for­ward with its once-dai­ly mon­o­clon­al an­ti­body for he­mo­phil­ia A or B treat­ment aim­ing to stop ex­ces­sive bleed­ing events be­fore they hap­pen, tout­in… [+3696 chars]

full article...